GLP-1 Drugs May Cut Cancer Risk in Obese Adults

A study of nondiabetic adults found those taking GLP-1 agonists had a 41% lower risk of certain cancers.

Updated on Oct. 30, 2026 in Weight Loss

Isometric editorial illustration of a glass pharmaceutical vial and medical pipette, representing clinical research on weight-management medication and health outcomes. — A study of over 161,000 adults suggests GLP-1 agonists, typically used for weight management, may be linked to a 41% reduced risk of obesity-related cancers. AI Illustration. Upload story photo >

Live Poll

Do you trust that weight-loss medications provide significant long-term health benefits for your own health?

A new study of over 161,000 nondiabetic adults with obesity found that GLP-1 receptor agonist use is associated with a 41% lower risk of 13 obesity-linked cancers. These findings, based on data collected through mid-2025, highlight a potential long-term health benefit for patients managing weight through these medications.

Why it matters

Obesity is a known risk factor for various malignancies, and understanding how weight-management interventions like GLP-1 agonists impact cancer development could change clinical approaches to long-term care. These results are preliminary and require further study to confirm how these drugs may influence cancer risk independently of weight loss.

This retrospective analysis of 161,798 nondiabetic adults with obesity used 1:1 propensity score matching to compare GLP-1 receptor agonist users against those receiving only lifestyle counseling. Participants had a median follow-up of 2 years, though researchers note that prospective trials are still required to confirm the findings.

The details

Investigators matched patients receiving GLP-1 agonists with individuals undergoing only diet or exercise counseling to isolate the potential protective effects of the medication. The analysis focused on 13 specific cancers known to be associated with obesity. While the results suggest a significant correlation with reduced risk, researchers emphasize that retrospective data cannot confirm a direct causal link or account for all confounding variables.

Data collection for the study population occurred from December 2014 to June 2025.
Study participants had a median follow-up period of 2 years.

Health Landscape

This study leverages the TriNetX national database to quantify the relationship between GLP-1 use and cancer incidence across a massive, real-world patient population. It adds to the evolving evidence base regarding the systemic health impacts of GLP-1 therapy beyond glycemic control and weight management.

If you are currently managing obesity with GLP-1 agonists, these findings offer a new area of research to discuss with your primary care provider during your next checkup. Do not view this data as a reason to alter your current treatment plan, as these retrospective results are not yet confirmed by clinical trials.

The takeaway

While the 41% reduction in cancer risk is significant, it remains a preliminary finding based on retrospective health records rather than a clinical trial. Keep track of your recommended cancer screenings and consult your doctor to understand how your weight-management journey fits into your overall cancer-prevention strategy.